8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 23, 2007

Shire plc

________________________________________________________________________________

(Exact name of registrant as specified in its charter)

England and Wales

________________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630 98-0484822

(Commission File Number) (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,

Hampshire RG24 8EP England

________________________________________________________________________________

(Address of principal executive offices)                          (Zip code)

Registrant's telephone number, including area code             44 1256 894 000

________________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

     Shire plc has issued the press release attached as Exhibit 99.01 which is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

                (d)  Exhibits.  The following exhibit is filed herewith:

99.01Press Release dated March 23, 2007

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/  A C Russell
	Name:Angus Russell
	Title   Chief Financial Officer

Dated: March 23, 2007

EXHIBIT INDEX
Number	Description
99.01	Press Release dated March 23, 2007

EX-99.1

	EXHIBIT 99.01
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

23 March 2007

Shire plc (the "Company")

Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities.

The Company was notified by Mr John Lee, Executive Vice President Global Supply Chain & Quality, on 22 March 2007, of the exercise in London on the same day, of an option over 35,000 ordinary 5p shares in the capital of the Company at an exercise price of £10.275. Mr Lee chose to use a net settled cashless exercise facility run by the Company which resulted in 2,305 shares being allotted to him. The option over the remaining 32,695 shares lapsed.

The Company was further notified, by Mr Lee, on 22 March 2007, of the sale in London on the same day of 2,305 ordinary 5p shares in the capital of the Company at a price of £11.00.

Following this transaction Mr Lee retains shares under option and stock appreciation rights in the Company totalling 224,923 ordinary shares.

T May

Company Secretary

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above